00000nam a22000004a 4500 UP-8027390931312107884 Buklod 20251001115054.0 m |o d | ta 250717s2025 xxu r |||| u|eng d PHARM rda eng LG 993.5 2025 P5 D45 De Lena, Baroness Maria S. author Treatment outcomes of statin dose optimization strategies in managing statin-associated muscle symptoms in a tertiary care hospitals: a retrospective cohort study Baroness Maria S. De Lena, Siegfried Kayne L. Lim, Vaughn Emil A. Lu ; Charles Mandy G. Ayran, adviser ; Rubina G. Reyes-Abaya, co-investigator. Department of Pharmacy, College of Pharmacy, University of the Philippines Manila 2025 xiv, 209 leaves ; 29 cm. Thesis (Bachelor of Science in Pharmacy)--University of the Philippines Manila, July 2025 available to general public Although the use of statins is prominent, current international and local guidelines have varying recommendations in the management strategies for statin-associated muscle symptoms (SAMS). The study primarily aims to explore the relationship between statin dose optimization strategies and muscle symptom improvement among patients with SAMS in a tertiary care hospital. Specifically, the study aims to describe the demographics of included patients, the cumulative incidence, the statin dose optimization strategies used in the study site, their respective treatment outcomes, and the association between these strategies and muscle symptom improvement among patients with SAMS. The study is a retrospective cohort records review that utilized total population purposive sampling. The study was conducted in a tertiary care hospital setting, where the sample population consists of adult in-patient statin users admitted between January to July 2024 who experienced muscle symptoms. Eligible records were further screened for SAMS before data analysis. A total of 61 out of 1,804 patients had experienced SAMS with the following demographics: females (60.66%), age of < 65 years old (59.02%), and with ≥ 3 comorbidities (68.85%). Although the majority of the patients did not receive any strategy (n = 20), the most implemented dose optimization strategy was statin discontinuation (n = 16). Statin switch has the highest incidence density for improvement of muscle symptoms (11.46 cases/100 patient-days), followed by discontinuation (10.94 cases/100 patient-days), lower dose (9.62 cases/100 patient-days), and no dose optimization strategy (6.25 cases/100 patient-days). The association between implementing dose optimization strategies and improvement of muscle symptoms was statistically significant (p = 0.0309). The cumulative incidence for patients with SAMS in the study was calculated at 3.40%, and implementing statin dose optimization strategies show promising evidence for improving muscle symptoms in statin users. Statins (Cardiovascular agents) Dose adjustment Muscle toxicity Philippines. Lim, Siegfried Kayne L. author. Lu, Vaughn Emil A. author . Ayran , Charles Mandy G. adviser. Reyes-Abaya, Rubina G. co-investigator. FI UP UPMNL PHARM LG 993.5 2025 P5 D45 Thesis